The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A

International Journal of Pharmaceutics

Volumn 492, Issue 1-2, 2015, Pages 169-176

  Agnolon, Valentina ^a,b   Bruno, Cristina ^a,c   Leuzzi, Rosanna ^a   Galletti, Bruno ^a   D'Oro, Ugo ^a   Pizza, Mariagrazia ^a   Seubert, Anja ^a   O'Hagan, Derek T ^d   Baudner, Barbara C ^a  

^a GSK   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvants; Mouse model; Pertussis; Vaccine formulation

Indexed keywords

ALUMINUM HYDROXIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; FILAMENTOUS HEMAGGLUTININ; HEMAGGLUTININ; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MIFAMURTIDE; PERTACTIN; PERTUSSIS TOXIN; PHOSPHORYL LIPID A; TETANUS TOXOID REDUCED DIPHTHERIA TOXOID AND ACELLULAR PERTUSSIS VACCINE; UNCLASSIFIED DRUG; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; DIPHTHERIA TOXIN; IMMUNOLOGICAL ADJUVANT; LIPID A; MF59 OIL EMULSION; POLYSORBATE; SQUALENE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EMULSION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; WESTERN BLOTTING; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BORDETELLA PERTUSSIS; CHEMISTRY; CHLOROCEBUS AETHIOPS; CHO CELL LINE; CRICETULUS; IMMUNOLOGY; TUMOR CELL LINE; VERO CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETULUS; DIPHTHERIA TOXIN; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPID A; MICE; MICE, INBRED BALB C; PERTUSSIS TOXIN; POLYSORBATES; SQUALENE; VERO CELLS;

EID: 84937836446     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.06.030     Document Type: Article

References (62)

1. C. Asokanathan, M. Corbel, and D. Xing A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis Hum. Vaccin. Immunother. 9 2 2013 325 331
2. L.A. Brito, P. Malyala, and D.T. O'Hagan Vaccine adjuvant formulations: a pharmaceutical perspective Semin. Immunol. 25 2013 130 145
3. L.P. Celentano, and et al. Resurgence of pertussis in Europe Pediatr. Infect. Dis. J. 24 9 2005 761 765
4. J.D. Cherry Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease N. Engl. J. Med. 367 9 2012 785 787
5. T. Clapp, and et al. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability J. Pharm. Sci. 100 2 2011 388 401
6. Centers for Disease Control and Prevention Pertussis epidemic - Washington, 2012 MMWR Morb. Mortal. Wkly. Rep. 61 28 2012 517 522
7. Centers for Disease Control and Prevention Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010 MMWR Morb. Mortal. Wkly. Rep. 60 1 2011 13
8. A.M. Didierlaurent, and et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity J. Immunol. 183 10 2009 6186 6197
9. M. Friedrich Research aims to boost pertussis control JAMA 306 1 2011 27 29
10. N. Garçon, M. Van Mechelen, and M. Wettendorff Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt V. Schijns, D. O'Hagan, Immunopotentiators in Modern Vaccines 2006 Elsevier Academic Press London, UK 161 177
11. N. Garçon, P. Chomez, and M. Van Mechelen GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives Expert Rev. Vaccines 6 2007 723 739
12. S. Garlapati, and et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis Vaccine 29 38 2011 6540 6548
13. J. Geurtsen, and et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice Clin. Vaccine Immunol. 14 7 2007 821 829
14. S.L. Giannini, and et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 33 2006 5937 5949
15. P. Gillenius, and et al. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells J. Biol. Stand. 13 1 1985 61 66
16. D.M. Granoff, and et al. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine Infect. Immun. 65 5 1997 1710 1715
17. N. Guiso Pertussis vaccination and whooping cough: and now what? Expert Rev. Vaccines 13 10 2014 1163 1165
18. R.K. Gupta Aluminum compounds as vaccine adjuvants Adv. Drug Deliv. Rev. 32 3 1998 155 172
19. U. Heininger Update on pertussis in children Expert Rev. Anti Infect. Ther. 8 2 2010 163 173
20. S.L. Hem, and H. HogenEsch Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation Expert Rev. Vaccines 6 2007 685 698
21. E. Hewlett, and et al. Adenylate cyclase toxin from Bordetella pertussis: current concepts and problems in the study of toxin functions Int. J. Med. Microbiol. 290 4 2000 333 335
22. R. Higgs, and et al. Immunity to the respiratory pathogen Bordetella pertussis Mucosal Immunol. 5 2012 485 500
23. M. Hijnen, and et al. Epitope structure of the Bordetella pertussis protein P. 69 pertactin, a major vaccine component and protective antigen Infect. Immun. 72 7 2004 3716 3723
24. H. HogenEsch Mechanism of immunopotentiation and safety of aluminum adjuvants Front. Immunol. 3 2012
25. D. Hozbor, and et al. Pertussis epidemiology in Argentina: trends over 2004-2007 J. Infect. 59 4 2009 225 231
26. X. Hu, R. Liu, and N. Zhu Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB/c mice Immunobiology 218 12 2013 1524 1528
27. A. Kimura, and et al. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model Infect. Immun. 58 1 1990 7 16
28. R. Libster, and K.M. Edwards Re-emergence of pertussis: what are the solutions? Expert Rev. Vaccines 11 11 2012 1331 1346
29. C. Locht, and N. Mielcarek New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol. Med. Microbiol. 66 2 2012 121 133
30. B.P. Mahon, M.T. Brady, and K.H. Mills Protection against Bovdetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children J. Infect. Dis. 181 6 2000 2087 2091
31. K. Mills, and et al. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model Infect. Immun. 61 2 1993 399 410
32. K.H. Mills, and et al. Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol. 22 2 2014 49 52
33. F.R. Mooi, and et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence Emerg. Infect. Dis. 15 8 2009 1206
34. E. Østergaard, and et al. Elimination of interfering activity in serum samples in the Chinese hamster ovary pertussis serology assay Clin. Vaccine Immunol. 15 8 2008 1244 1247
35. D.T. O'Hagan, and N.M. Valiante Recent advances in the discovery and delivery of vaccine adjuvants Nat. Rev. Drug Discov. 2 9 2003 727 735
36. D. O'Hagan, A. Wack, and A. Podda MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82 6 2007 740 744
37. D.T. O'Hagan, G.S. Ott, G.V. Nest, R. Rappuoli, and G.D. Giudice The history of MF59 adjuvant: a phoenix that arose from the ashes Expert Rev. Vaccines 12 2013 13 30
38. G. Ott, and et al. The adjuvant MF59: a 10-year perspective Meth. Mol. Med. 42 2000 211 228
39. J. Petre, and et al. The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization Dev. Biol. Stand. 87 1995 125 134
40. M. Pizza, and et al. Mutants of pertussis toxin suitable for vaccine development Science 246 4929 1989 497 500
41. A. Podda, and G. Del Giudice Mf59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile Expert Rev. Vaccines 2 2003 197 203
42. A. Podda, and et al. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G J. Exp. Med. 172 3 1990 861 868
43. A. Podda, G. Del Giudice, and D. O'Hagan MF59: A Safe and Potent Adjuvant for Human Use 2006 Elsevier Press USA
44. M. Polewicz, and et al. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies Vaccine 31 31 2013 3148 3155
45. M. Roberts, and et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity: PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins Infect. Immun. 63 6 1995 2100 2108
46. P.J. Ross, and et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine PLoS Pathog. 9 4 2013 e1003264
47. M. Ryan, and et al. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28 Int. Immunol. 10 5 1998 651 662
48. E.D. Shapiro Acellular vaccines and resurgence of pertussis JAMA 308 20 2012 2149 2150
49. S. Sharma, and et al. Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles J. Pharm. Sci. 101 1 2012 233 244
50. M. Singh, and et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens Vaccine 24 10 2006 1680 1686
51. P. Smith, and et al. Measurement of protein using bicinchoninic acid Anal. Biochem. 150 1 1985 76 85
52. T. Tan, E. Trindade, and D. Skowronski Epidemiology of pertussis Pediatr. Infect. Dis. J. 24 5 2005 S10 S18
53. B.E. Tefon, E. Özcengiz, and G. Özcengiz Pertussis vaccines: state-of-the-art and future trends Curr. Top. Med. Chem. 13 20 2013 2581 2596
54. H. Thompson, and et al. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A Vaccine 16 20 1998 1993 1999
55. P. Traquina, and et al. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates J. Infect. Dis. 174 6 1996 1168 1175
56. ® immunostimulant: adjuvant formulations D.T. O'Hagan, Adjuvants: Preparation methods and Research Protocols 2000 Humana Press, Inc. NJ, USA 273 282
57. M. Vajdy, and et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses J. Gen. Virol. 87 8 2006 2253 2262
58. S. Vecchi, and et al. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations J. Pharm. Sci. 101 1 2012 17 20
59. T. Vesikari, and et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence Pediatrics 126 4 2010 e762 e770
60. A. Wack, and et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice Vaccine 26 4 2008 552 561
61. J.M. Warfel, and et al. Nonhuman primate model of pertussis Infect. Immun. 80 4 2012 1530 1536
62. A. Zeddeman, and et al. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012 Euro Surveill. 19 33 2014